Array BioPharma Company Profile (NASDAQ:ARRY)

About Array BioPharma (NASDAQ:ARRY)

Array BioPharma logoArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARRY
  • CUSIP: 04269X10
  • Web:
  • Market Cap: $1.40739 billion
  • Outstanding Shares: 170,800,000
Average Prices:
  • 50 Day Moving Avg: $8.26
  • 200 Day Moving Avg: $9.31
  • 52 Week Range: $3.10 - $13.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.26
  • P/E Growth: -1.10
Sales & Book Value:
  • Annual Revenue: $41.51 million
  • Price / Sales: 33.90
  • Book Value: $0.16 per share
  • Price / Book: 51.50
  • EBIDTA: ($96,300,000.00)
  • Net Margins: -70.03%
  • Return on Assets: -51.95%
  • Debt-to-Equity Ratio: 4.31%
  • Current Ratio: 3.47%
  • Quick Ratio: 3.47%
  • Average Volume: 3.44 million shs.
  • Beta: 2.23
  • Short Ratio: 4.12
Frequently Asked Questions for Array BioPharma (NASDAQ:ARRY)

What is Array BioPharma's stock symbol?

Array BioPharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array BioPharma's earnings last quarter?

Array BioPharma Inc. (NASDAQ:ARRY) released its earnings results on Wednesday, May, 10th. The company reported ($0.21) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.05. The firm earned $33.28 million during the quarter, compared to the consensus estimate of $38.28 million. The firm's revenue for the quarter was down 22.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) EPS. View Array BioPharma's Earnings History.

When will Array BioPharma make its next earnings announcement?

Array BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Array BioPharma.

Where is Array BioPharma's stock going? Where will Array BioPharma's stock price be in 2017?

7 brokerages have issued 12 month price targets for Array BioPharma's shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate Array BioPharma's share price to reach $11.86 in the next year. View Analyst Ratings for Array BioPharma.

What are analysts saying about Array BioPharma stock?

Here are some recent quotes from research analysts about Array BioPharma stock:

  • 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (7/11/2017)
  • 2. Cowen and Company analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)

Who are some of Array BioPharma's key competitors?

Who are Array BioPharma's key executives?

Array BioPharma's management team includes the folowing people:

  • Kyle A. Lefkoff, Independent Chairman of the Board
  • Ron R. Squarer, Chief Executive Officer, Director
  • Jason Haddock, Chief Financial Officer
  • Andrew R. Robbins, Chief Operating Officer
  • Nicholas A. Saccomano Ph.D., Chief Scientific Officer
  • John R. Moore, Vice President, General Counsel, Secretary
  • Victor Sandor, Chief Medical Officer
  • Shalini Sharp, Director
  • Charles M. Baum M.D., Ph.D., Independent Director
  • Gwendolyn A. Fyfe M.D., Independent Director

Who owns Array BioPharma stock?

Array BioPharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Handelsbanken Fonder AB (0.28%), Nisa Investment Advisors LLC (0.11%), Bank of Montreal Can (0.10%), Hollencrest Securities LLC (0.08%), Fisher Asset Management LLC (0.08%) and Handelsinvest Investeringsforvaltning (0.06%). Company insiders that own Array BioPharma stock include Charles M Baum and Redmile Group, Llc. View Institutional Ownership Trends for Array BioPharma.

Who sold Array BioPharma stock? Who is selling Array BioPharma stock?

Array BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Aperio Group LLC. Company insiders that have sold Array BioPharma stock in the last year include Charles M Baum and Redmile Group, Llc. View Insider Buying and Selling for Array BioPharma.

Who bought Array BioPharma stock? Who is buying Array BioPharma stock?

Array BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Bank of Montreal Can, Handelsinvest Investeringsforvaltning, Fisher Asset Management LLC, Creative Planning, Quantitative Systematic Strategies LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Array BioPharma.

How do I buy Array BioPharma stock?

Shares of Array BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array BioPharma's stock price today?

One share of Array BioPharma stock can currently be purchased for approximately $8.24.

MarketBeat Community Rating for Array BioPharma (NASDAQ ARRY)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Array BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Array BioPharma (NASDAQ:ARRY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $11.86 (43.90% upside)

Analysts' Ratings History for Array BioPharma (NASDAQ:ARRY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Piper Jaffray CompaniesSet Price TargetBuy$14.00LowView Rating Details
7/18/2017Cantor FitzgeraldReiterated RatingBuy$13.00LowView Rating Details
5/6/2017Jefferies Group LLCSet Price TargetBuy$8.00HighView Rating Details
5/3/2017J P Morgan Chase & CoUpgradeNeutral -> Overweight$9.00 -> $10.00LowView Rating Details
3/20/2017Cowen and CompanyLower Price TargetOutperform$14.00HighView Rating Details
2/3/2017Stifel NicolausBoost Price TargetBuy$8.00 -> $13.00N/AView Rating Details
1/30/2017Leerink SwannDowngradeOutperform -> Market Perform$11.00N/AView Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$7.00N/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for Array BioPharma (NASDAQ:ARRY)
Earnings by Quarter for Array BioPharma (NASDAQ:ARRY)
Earnings History by Quarter for Array BioPharma (NASDAQ ARRY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($0.21)N/AView Earnings Details
5/10/2017Q3 2017($0.16)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Array BioPharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($0.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.21)($0.22)
Q2 20173($0.27)($0.20)($0.22)
Q3 20173($0.31)($0.22)($0.25)
Q4 20173($0.29)($0.21)($0.25)
Q1 20181($0.22)($0.22)($0.22)
Q2 20181($0.23)($0.23)($0.23)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)


Dividend History for Array BioPharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Array BioPharma (NASDAQ:ARRY)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 97.88%
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array BioPharma (NASDAQ:ARRY)
Insider Trades by Quarter for Array BioPharma (NASDAQ:ARRY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.00View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Array BioPharma (NASDAQ:ARRY)
Latest Headlines for Array BioPharma (NASDAQ:ARRY)
DateHeadline logoNew Strong Sell Stocks for July 20th - Nasdaq - July 20 at 5:31 PM logoColorado biotech makes deal with industry giant - Denver Business Journal - July 18 at 5:33 PM logoArray BioPharma Inc. (NASDAQ:ARRY) Given a $14.00 Price Target by Piper Jaffray Companies Analysts - July 18 at 5:31 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of ... - Business Wire (press release) - July 14 at 10:55 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Array BioPharma Inc. - July 14 at 5:54 PM logoETFs with exposure to Array BioPharma, Inc. : July 12, 2017 - July 12 at 4:31 PM logoArray BioPharma Inc. (NASDAQ:ARRY) Downgraded by Zacks Investment Research - July 11 at 11:26 PM logoArray BioPharma Inc. (NASDAQ:ARRY) Receives Consensus Recommendation of "Buy" from Analysts - July 11 at 8:26 AM logoImplied Volatility Surging for Array BioPharma Inc. (ARRY) Stock Options - Nasdaq - July 10 at 4:00 PM logoImplied Volatility Surging for Array BioPharma Inc. (ARRY) Stock Options - July 10 at 4:00 PM logoArray BioPharma Submits NDAs For Binimetinib & Encorafenib In Advanced Melanoma - July 5 at 4:40 PM logoArray BioPharma Submits New Drug Applications To FDA For Binimetinib And Encorafenib In Advanced Melanoma - July 5 at 4:40 PM logo$30.60 Million in Sales Expected for Array BioPharma Inc. (ARRY) This Quarter - July 1 at 9:44 AM logoZacks: Analysts Anticipate Array BioPharma Inc. (ARRY) Will Post Earnings of -$0.21 Per Share - June 29 at 7:49 AM logoCommit To Buy Array BioPharma At $4, Earn 13.8% Using Options - Nasdaq - June 27 at 3:47 PM logoETFs with exposure to Array BioPharma, Inc. : June 27, 2017 - June 27 at 3:47 PM logoArray BioPharma Inc. (ARRY) Upgraded at BidaskClub - June 24 at 10:58 PM logoAre Options Traders Betting on a Big Move in Array BioPharma (ARRY) Stock? - June 23 at 4:15 PM logoPre-Market Technical Recap on Biotech Stocks -- Array BioPharma ... - PR Newswire (press release) - June 21 at 4:31 PM logoArray BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : June 21, 2017 - June 21 at 4:31 PM logoARRY Crosses Above Key Moving Average Level - June 21 at 2:21 AM logoETFs with exposure to Array BioPharma, Inc. : June 16, 2017 - June 16 at 4:20 PM logoArray BioPharma Inc. (ARRY) Receives Consensus Rating of "Buy" from Analysts - June 16 at 8:17 AM logoArray BioPharma, Inc. :ARRY-US: Earnings Analysis: Q3, 2017 By the Numbers : June 14, 2017 - June 14 at 10:07 AM logoArray BioPharma Inc. (ARRY) Upgraded at ValuEngine - June 12 at 11:36 PM logoArray BioPharma Inc. (ARRY) Short Interest Down 1.9% in May - June 12 at 7:54 AM logoJim Cramer Shares His Thoughts On Foot Locker, Array Biopharma And Ulta Beauty - Benzinga - June 9 at 3:58 PM logo Brokerages Expect Array Biopharma Inc (ARRY) Will Announce Quarterly Sales of $30.60 Million - June 7 at 12:50 PM logoWhy Array BioPharma Inc. Sank 13.5% in May - Motley Fool - June 5 at 11:18 PM logoWhy Array BioPharma Inc. Sank 13.5% in May - June 5 at 6:17 PM logoArray Biopharma Inc (ARRY) Expected to Post Earnings of -$0.21 Per Share - June 5 at 8:00 AM logoArray Biopharma Inc (ARRY) Given a $14.00 Price Target at Piper Jaffray Companies - June 1 at 11:34 PM logoBlog Coverage: Array BioPharma and Bristol-Myers Squibb Partner to Investigate Combinations of Binimetinib, Opdivo, and Yervoy in Colorectal Cancer Patients - June 1 at 3:55 PM logoArray Biopharma To Present At The Goldman Sachs 38th Annual Global Healthcare Conference - June 1 at 3:55 PM logoBristol-Myers Partners Array to Investigate Cancer Candidate - May 31 at 3:38 PM logoBUZZ-U.S. STOCKS ON THE MOVE-Danaos, Michael Kors, Array Biopharma, MabVax, EnteroMedics - Nasdaq - May 31 at 10:31 AM logoArray BioPharma And Ono Pharmaceutical Co., Ltd. Announce A ... - PR Newswire (press release) - May 31 at 10:31 AM logoArray BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib - May 31 at 10:31 AM logoBiotech Movers: Akari, Array, Amicus - May 31 at 10:31 AM logoBristol-Myers Hookup Boosts Array BioPharma - - May 30 at 9:03 PM logoBUZZ-U.S. STOCKS ON THE MOVE-Array BioPharma, Seadrill, LG ... - Nasdaq - May 30 at 3:43 PM logoArray Biopharma Inc (ARRY) Given Average Recommendation of "Buy" by Brokerages - May 22 at 7:56 AM logoLeerink Swann Weighs in on Array Biopharma Inc's FY2017 Earnings (ARRY) - May 17 at 9:10 AM logoEdited Transcript of ARRY earnings conference call or presentation 10-May-17 1:00pm GMT - May 16 at 8:44 PM logoSunTrust Banks Brokers Lift Earnings Estimates for Array Biopharma Inc (ARRY) - May 15 at 8:52 AM logoFY2017 Earnings Forecast for Array Biopharma Inc (ARRY) Issued By Jefferies Group - May 12 at 1:18 PM logoArray BioPharma's (ARRY) CEO Ron Squarer on Q1 2017 Results - Earnings Call Transcript - May 11 at 9:02 PM logoHere's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today - Motley Fool - May 11 at 4:00 PM logoToday's Research Reports on Stocks to Watch: Array Biopharma and Verastem - May 11 at 4:00 PM logoJefferies Group Weighs in on Array Biopharma Inc's Q1 2018 Earnings (ARRY) - May 11 at 1:30 PM



Array BioPharma (ARRY) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff